Planning Grant for a Study of the Effect of Radiation

辐射影响研究规划拨款

基本信息

项目摘要

There are several reports of studies that suggest an association between exposure to ionizing radiation and the subsequent development of breast cancer. Despite the dramatic increase in thyroid cancer after radiation exposure from the Chernobyl accident in 1986, especially in young children, there are no reports of studies of women in the same exposed population of the incidence of breast cancer, or of additional risks for the development of breast cancer. Like the thyroid, the human breast concentrates iodine and women near Chernobyl were exposed to much higher than normal levels of radioiodine and other radioactive isotopes, especially cesium and strontium. Moreover, as the breast develops and changes throughout various points in a woman's life (in utero, during puberty, pregnancy and lactation), there are distinct periods of time when the breast is more susceptible to environmental exposures. These observations, together with previous evidence linking ionizing radiation to breast cancer suggests that exposure to the nuclear radiation at Chernobyl will likely result in an increase In breast cancer, especially among particularly vulnerable subpopulations, such as women who were in utero, entering puberty, pregnant or lactating at the time of the accident or who harbor a particular genetic predisposition to the disease. Hence an investigation of the role of genetic and lifestyle factors associated with nuclear radiation in women exposed to the Chernobyl fallout is warranted. Such an investigation will help us further understand radiation-induced breast cancer and factors that may modify that relationship. This R03 application proposes the following objectives in preparation for a subsequent study to evaluate breast cancer in an Eastern European population exposed to sustained high doses of ionizing radiation in 1986: 1. Initiate and establish relationships with investigators in Belarus in order to set up the infrastructure for the pilot study and the resulting R01 study; 2. Link the Belarusian Radiation Exposure database to the cancer registry database in order to identify cases associated with various levels of radiation exposure. A subset of these cases will serve as the pilot study. Age and residence matched healthy women identified through the Radiation Exposure database will serve as controls; 3. Establish and test the study infrastructure, including instrument design, specimen acquisition, and laboratory testing; and 4. Generate pilot data in support of an R01 application. By the end of this two year period, we will have put into place all the necessary mechanisms to conduct a large-scale population based study, and we will have gathered pilot data to support an R01 application investigating nuclear radiation exposure and breast cancer.
有几份研究的报道表明,暴露于电离辐射与随后的乳腺癌发展之间存在关联。尽管1986年切尔诺贝利事故暴露后的甲状腺癌急剧增加,尤其是在幼儿中,但尚无关于乳腺癌发病率相同的女性的研究,也没有乳腺癌发展的额外风险。像甲状腺一样,人类乳房浓缩碘和切尔诺贝利附近的妇女的暴露于低于正常水平的放射性碘和其他放射性同位素,尤其是剖腹产和锶。此外,随着乳房在女性生活中的各个地方的发展和变化(在子宫内,青春期,怀孕和哺乳期),在乳房更容易受到环境暴露更容易受到影响的不同时期。这些观察结果以及以前将电离辐射与乳腺癌联系起来的证据表明,切尔诺贝利的核辐射暴露可能会导致乳腺癌的增加,尤其是在尤其是易受伤害的亚群中,例如在子宫内,在意外或伴有特定遗传遗传疾病时进入青春期,孕妇或哺乳。因此,有必要对与核辐射相关的遗传和生活方式因素的作用进行研究。这样的研究将有助于我们进一步了解辐射引起的乳腺癌以及可能改变这种关系的因素。该R03的应用提出了以下目标,以准备一项随后的研究,以评估1986年的东欧人群中的乳腺癌,该研究在1986年受到持续的高剂量电离辐射,以启动白俄罗斯的研究并建立关系,以建立试验性研究的基础架构和结果研究; 2。将白俄罗斯辐射暴露数据库与癌症注册表数据库联系起来,以识别与各种辐射暴露相关的病例。这些病例的一部分将作为试点研究。通过辐射暴露数据库确定的年龄和居住与健康女性相匹配,将作为对照。 3。建立和测试研究基础设施,包括仪器设计,标本采集和实验室测试;和4。生成试点数据以支持R01应用程序。到这两年期结束时,我们将提出所有必要的机制来进行大规模的基于人群的研究,我们将收集试点数据,以支持R01申请研究核辐射暴露和乳腺癌。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

FRANCESMARY MODUGNO其他文献

FRANCESMARY MODUGNO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('FRANCESMARY MODUGNO', 18)}}的其他基金

CEP: Career Enhancement Program
CEP:职业提升计划
  • 批准号:
    10713059
  • 财政年份:
    2023
  • 资助金额:
    $ 7.43万
  • 项目类别:
Core B: TCP: Translational Pathology Core
核心 B:TCP:转化病理学核心
  • 批准号:
    10713055
  • 财政年份:
    2023
  • 资助金额:
    $ 7.43万
  • 项目类别:
Multi-omic Predictive Markers for Ovarian Cancer Therapy Response and Outcomes
卵巢癌治疗反应和结果的多组学预测标记
  • 批准号:
    10351697
  • 财政年份:
    2022
  • 资助金额:
    $ 7.43万
  • 项目类别:
Multi-omic Predictive Markers for Ovarian Cancer Therapy Response and Outcomes
卵巢癌治疗反应和结果的多组学预测标记
  • 批准号:
    10678828
  • 财政年份:
    2022
  • 资助金额:
    $ 7.43万
  • 项目类别:
NOVEL RISK FACTOR AND POTENTIAL EARLY DETECT MARK OVARIAN CANCER
新的风险因素和潜在的早期检测马克卵巢癌
  • 批准号:
    7201102
  • 财政年份:
    2005
  • 资助金额:
    $ 7.43万
  • 项目类别:
HORMONE METABOLISM AND BREAST MASSES
激素代谢和乳房质量
  • 批准号:
    7201154
  • 财政年份:
    2005
  • 资助金额:
    $ 7.43万
  • 项目类别:
Ovarian Cancer: Prevention and Its Recurrence
卵巢癌:预防及其复发
  • 批准号:
    7124957
  • 财政年份:
    2004
  • 资助金额:
    $ 7.43万
  • 项目类别:
The Role of Prolactin in Postmenopausal Breast Cancer
催乳素在绝经后乳腺癌中的作用
  • 批准号:
    6948505
  • 财政年份:
    2004
  • 资助金额:
    $ 7.43万
  • 项目类别:
Ovarian Cancer: Prevention and Its Recurrence
卵巢癌:预防及其复发
  • 批准号:
    6838458
  • 财政年份:
    2004
  • 资助金额:
    $ 7.43万
  • 项目类别:
Hormone Metabolism and Breast Masses
激素代谢和乳房肿块
  • 批准号:
    6974754
  • 财政年份:
    2004
  • 资助金额:
    $ 7.43万
  • 项目类别:

相似国自然基金

BRCA1/2基因不同突变位点对对侧乳腺癌发病风险的差异影响及其机制探索
  • 批准号:
    82372717
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
调控BRCA1突变乳腺癌PARP抑制剂应答的关键增强子及其下游基因研究
  • 批准号:
  • 批准年份:
    2023
  • 资助金额:
    220 万元
  • 项目类别:
调控BRCA1突变乳腺癌PARP抑制剂应答的关键增强子及其下游基因研究
  • 批准号:
    82330090
  • 批准年份:
    2023
  • 资助金额:
    220.00 万元
  • 项目类别:
    重点项目
BRCA2基因新突变导致的甲基缺失引起高危家族卵巢/乳腺癌发生的机制研究
  • 批准号:
    81972444
  • 批准年份:
    2019
  • 资助金额:
    55 万元
  • 项目类别:
    面上项目
雄激素刺激共转录导致R-LOOPs形成诱导DNA损伤促进AR+三阴乳腺癌发生发展的实验研究
  • 批准号:
    81773279
  • 批准年份:
    2017
  • 资助金额:
    54.0 万元
  • 项目类别:
    面上项目

相似海外基金

Information-Theoretic Surprise-Driven Approach to Enhance Decision Making in Healthcare
信息论惊喜驱动方法增强医疗保健决策
  • 批准号:
    10575550
  • 财政年份:
    2023
  • 资助金额:
    $ 7.43万
  • 项目类别:
Small molecules targeting RuvBL complex for triple negative breast cancer
靶向 RuvBL 复合物的小分子治疗三阴性乳腺癌
  • 批准号:
    10751401
  • 财政年份:
    2023
  • 资助金额:
    $ 7.43万
  • 项目类别:
Synergize a novel homologous recombination inhibitor with DNA damagingagents in TNBC
在 TNBC 中协同新型同源重组抑制剂与 DNA 损伤剂
  • 批准号:
    10760604
  • 财政年份:
    2023
  • 资助金额:
    $ 7.43万
  • 项目类别:
Landscape and characterization of promoter mutations driving triple-negative breast cancer
驱动三阴性乳腺癌的启动子突变的景观和特征
  • 批准号:
    10751219
  • 财政年份:
    2023
  • 资助金额:
    $ 7.43万
  • 项目类别:
Regulation of APOBEC3 cytidine deaminase-induced mutation during cancer development
癌症发展过程中 APOBEC3 胞苷脱氨酶诱导突变的调控
  • 批准号:
    10583753
  • 财政年份:
    2023
  • 资助金额:
    $ 7.43万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了